GENENTECH, INC for GENENTECH INC
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Issues relating to U.S. trade policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI KOGAN | Assistant Director |
Pharmacy PHA
Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies; 340(b) Drug Discount Program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| ELI KOGAN | Assistant Director |
| KATHERINE RAAB | Director |
Copyright/Patent/Trademark CPT
Transpacific Partnership Agreement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELI KOGAN | Assistant Director |
Taxation/Internal Revenue Code TAX
general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned US corporations. Follow issues related tax reform; Corporate tax reform; Issues relating to corporate tax reform including the R&D tax credit andtaxation of foreign-owned corporations with US subsidiaries
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| ELI KOGAN | Assistant Director |
Health Issues HCR
Patent Terms, Pandemic Preparedness, Tamiflu Stockpile, Appropriations; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", HR 1919 "Safeguarding America's Pharmaceuticals Act", Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54), Pharma supply chain issues, Issues related to 340b program; Ongoing issues related to the implementation of the Affordable Care Act of 2010; Drug pricing under 340B program
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| ANNA GRIFFIN | Sr. Director |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
Concerns regarding Medicare policies for Part B drugs. Issues related to the 340B Drug discount program; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and Medicare Part B reimbursement for physicians and related provisions of The Affordable Care Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| ANNA GRIFFIN | Sr. Director |
Budget/Appropriations BUD
Issues related to FDA & HHS program funding, FY16 Labor Health and Human Services, and Education, and Related Agencies, and FY 16 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills; Following issues related to the budget and appropriations process. Issues related to FY 2015 Departments of Labor, Health and Human Services, and Education, and related agencies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNA GRIFFIN | Sr. Director |
| ELI KOGAN | Assistant Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.